Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis

Overview

Journal J Pers Med

Date 2021 Apr 30

PMID 33922540

Citations 7

Authors

Maria Jose Zarzuelo Romero

Cristina Perez Ramirez

Maria Isabel Carrasco Campos

Almudena Sanchez Martin

Miguel Angel Calleja Hernandez

Maria Carmen Ramirez Tortosa

Alberto Jimenez Morales

Affiliations

Soon will be listed here.

Abstract

The introduction of new therapies for the treatment of multiple sclerosis (MS) is a very recent phenomenon and little is known of their mechanism of action. Moreover, the response is subject to interindividual variability and may be affected by genetic factors, such as polymorphisms in the genes implicated in the pathologic environment, pharmacodynamics, and metabolism of the disease or in the mechanism of action of the medications, influencing the effectiveness of these therapies. This review evaluates the impact of pharmacogenetics on the response to treatment with new therapies in patients diagnosed with MS. The results suggest that polymorphisms detected in the , , , , and genes, for treatment with natalizumab, , for fingolimod and dimethyl fumarate, , for cladribine, and , for dimethyl fumarate, may be used in the future as predictive markers of treatment response to new therapies in MS patients. However, there are few existing studies and their samples are small, making it difficult to generalize the role of these genes in treatment with new therapies. Studies with larger sample sizes and longer follow-up are therefore needed to confirm the results of these studies.

Citing Articles

Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.

Clarelli F, Corona A, Paakkonen K, Sorosina M, Zollo A, Piehl F J Neurol. 2024; 271(11):7250-7263.

PMID: 39264442 PMC: 11561017. DOI: 10.1007/s00415-024-12608-6.

NADPH Oxidase 3: Beyond the Inner Ear.

Herb M Antioxidants (Basel). 2024; 13(2).

PMID: 38397817 PMC: 10886416. DOI: 10.3390/antiox13020219.

Impact of NQO1 dysregulation in CNS disorders.

Yuhan L, Khaleghi Ghadiri M, Gorji A J Transl Med. 2024; 22(1):4.

PMID: 38167027 PMC: 10762857. DOI: 10.1186/s12967-023-04802-3.

Reshaping neuroimmunology: diagnosis and treatment in the era of precision medicine.

Dos Passos G, Adoni T, Mendes M, Sato D Arq Neuropsiquiatr. 2023; 81(12):1125-1133.

PMID: 38157878 PMC: 10756840. DOI: 10.1055/s-0043-1777752.

Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study.

Amin N, Abd El-Aziz M, Hamed M, Moustafa R, El Tayebi H Front Immunol. 2023; 14:1087595.

PMID: 36883100 PMC: 9985893. DOI: 10.3389/fimmu.2023.1087595.

References

Barnes T, PARRY P, Hart I, Jones C, Minet M, Patterson D . Regional mapping of the gene encoding dihydroorotate dehydrogenase, an enzyme involved in UMP synthesis, electron transport, and superoxide generation, to human chromosome region 16q22. Somat Cell Mol Genet. 1993; 19(4):405-11. DOI: 10.1007/BF01232751. View

Board P, Coggan M, Woodcock D . The human Pi class glutathione transferase sequence at 12q13-q14 is a reverse-transcribed pseudogene. Genomics. 1992; 14(2):470-3. DOI: 10.1016/s0888-7543(05)80243-5. View

Pawlik A, Herczynska M, Kurzawski M, Safranow K, Dziedziejko V, Drozdzik M . The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics. 2009; 10(2):303-9. DOI: 10.2217/14622416.10.2.303. View

Stampanoni Bassi M, Buttari F, Simonelli I, Gilio L, Furlan R, Finardi A . A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment. Genes (Basel). 2020; 11(10). PMC: 7601054. DOI: 10.3390/genes11101152. View

Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G . In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. Eur J Clin Pharmacol. 2017; 74(4):455-464. PMC: 5849655. DOI: 10.1007/s00228-017-2404-2. View

Hale G . The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2002; 3(3):137-43. DOI: 10.1080/146532401753174098. View

Hohlfeld R, Meinl E . Ocrelizumab in multiple sclerosis: markers and mechanisms. Lancet Neurol. 2017; 16(4):259-261. DOI: 10.1016/S1474-4422(17)30048-0. View

Rice G, Filippi M, Comi G . Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology. 2000; 54(5):1145-55. DOI: 10.1212/wnl.54.5.1145. View

Samuraki M, Sakai K, Odake Y, Yoshita M, Misaki K, Nakada M . Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid. Mult Scler Relat Disord. 2017; 13:44-46. DOI: 10.1016/j.msard.2017.02.005. View

10.

Havrdova E, Arnold D, Cohen J, Hartung H, Fox E, Giovannoni G . Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017; 89(11):1107-1116. PMC: 5595278. DOI: 10.1212/WNL.0000000000004313. View

11.

Freal J, Kraft G, Coryell J . Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984; 65(3):135-8. View

12.

Ruckemann K, Fairbanks L, Carrey E, Hawrylowicz C, Richards D, Kirschbaum B . Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. 1998; 273(34):21682-91. DOI: 10.1074/jbc.273.34.21682. View

13.

OSullivan C, Dev K . The structure and function of the S1P1 receptor. Trends Pharmacol Sci. 2013; 34(7):401-12. DOI: 10.1016/j.tips.2013.05.002. View

14.

Huth F, Gardin A, Umehara K, He H . Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations. Clin Pharmacol Ther. 2019; 106(5):1113-1124. PMC: 6851657. DOI: 10.1002/cpt.1547. View

15.

Cherwinski H, Cohn R, Cheung P, Webster D, Xu Y, Caulfield J . The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther. 1995; 275(2):1043-9. View

16.

Haider L, Fischer M, Frischer J, Bauer J, Hoftberger R, Botond G . Oxidative damage in multiple sclerosis lesions. Brain. 2011; 134(Pt 7):1914-24. PMC: 3122372. DOI: 10.1093/brain/awr128. View

17.

Hauser S, Oksenberg J . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006; 52(1):61-76. DOI: 10.1016/j.neuron.2006.09.011. View

18.

Carlstrom K, Ewing E, Granqvist M, Gyllenberg A, Aeinehband S, Enoksson S . Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019; 10(1):3081. PMC: 6626021. DOI: 10.1038/s41467-019-11139-3. View

19.

Marshall O, Lu H, Brisset J, Xu F, Liu P, Herbert J . Impaired cerebrovascular reactivity in multiple sclerosis. JAMA Neurol. 2014; 71(10):1275-81. PMC: 4376108. DOI: 10.1001/jamaneurol.2014.1668. View

20.

Rao S, Sancho J, Campos-Rivera J, Boutin P, Severy P, Weeden T . Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One. 2012; 7(6):e39416. PMC: 3382607. DOI: 10.1371/journal.pone.0039416. View